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Abstract
Background: The signal transducer and activator of transcription (STAT) family of
transcription factors mediates a variety of cytokine dependent gene regulations. STAT1
has been mainly characterized by its role in interferon (IFN) type I and II signaling and
STAT1 deficiency leads to high susceptibility to several pathogens. For fine-tuned
analysis of STAT1 function we established a dimerizer-inducible system for STAT1
expression in vitro and in vivo.
Results: The functionality of the dimerizer-induced STAT1 system is demonstrated in
vitro in mouse embryonic fibroblasts and embryonic stem cells. We show that this two-
vector based system is highly inducible and does not show any STAT1 expression in the
absence of the inducer. Reconstitution of STAT1 deficient cells with inducible STAT1
restores IFNγ-mediated gene induction, antiviral responses and STAT1 activation
remains dependent on cytokine stimulation. STAT1 expression is induced rapidly upon
addition of dimerizer and expression levels can be regulated in a dose-dependent
manner. Furthermore we show that in transgenic mice STAT1 can be induced upon
stimulation with the dimerizer, although only at low levels.
Conclusion: These results prove that the dimerizer-induced system is a powerful tool
for STAT1 analysis in vitro and provide evidence that the system is suitable for the use
in transgenic mice. To our knowledge this is the first report for inducible STAT1
expression in a time- and dose-dependent manner.
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Background
The JAK-STAT pathway is known to play a pivotal role in
a variety of different cytokine cascades. JAKs (Janus
kinases) are associated with intracellular domains of
receptors and become phosphorylated after ligand bind-
ing and aggregation of respective receptor chains. Acti-
vated JAKs phosphorylate tyrosine residues of the
receptor, thereby providing docking sites for STATs (signal
transducers and activators of transcription). STATs are in
turn phosphorylated on tyrosine and/or serine residues,
form homo- and/or heterodimers, translocate to the
nucleus and activate transcription of stimulus-dependent
genes [1-3]. Seven mammalian members of the STAT fam-
ily are known (STAT1, 2, 3, 4, 5a, 5b, and 6) and they all
share common features and structure. They have an ami-
noterminal DNA-binding domain, a carboxyterminal
transactivation domain and SH2 domains for interaction
with tyrosine phosphorylation sites [4,5]. STAT1 knock-
out mice show impaired response to interferon (IFN) type
I and II leading to high susceptibility to viruses and other
pathogens [6,7]. In addition, STAT1 is known to be
involved in mechanisms like cell growth, proliferation
and apoptosis [8] and phosphorylation-independent
STAT1 functions have been postulated [9]. Based on the
multiple functions of STAT1 identified through the gener-
ation of STAT1 knockout mice, our aim was to establish a
system to study STAT1 gene function in a spatiotemporal
and dose-dependent manner. In addition, we and others
reported clearly reduced STAT1 protein levels in mice defi-
cient for certain components of the IFN and TLR (toll-like
receptor) signaling cascades [10,11]. Availability of STAT1
protein is critical for a number of host cell responses and
limitations may well contribute to the phenotype of these
mice. A system for regulated STAT1 expression would
additionally provide a tool for uncoupling effects caused
by STAT1 protein levels from the phenotype due to tar-
geted deletion of the gene of interest.
During the last decade several inducible expression sys-
tems have been described and although a lot of improve-
ments have been implemented they all have certain
limitations [12]. For our purpose, high inducibility, tight
regulation, suitability for in vivo pathogen challenges and,
importantly, absence of basal transcriptional activity are
the major requirements. These criteria have been
described for rapamycin-regulated expression systems
[13]. These systems are based on rapamycin-induced
dimerization of two fusion proteins of a rapamycin bind-
ing domain each fused to a transactivation domain (TAD)
or a DNA-binding domain (DBD), respectively. Both
fusion proteins are expressed constitutively from a bicis-
tronic mRNA. Upon rapamycin treatment DBD and TAD
dimerize to form a functional transcription factor and in
turn activate transcription from a recognition site posi-
tioned upstream of the target gene. Mutations in the
rapamycin binding domain have made the use of non-
immunosuppressive analogs (rapalogs) possible [14].
Rapamycin and rapalogs are orally applicable, have pro-
longed pharmacokinetics and can cross the blood brain
barrier. The rapamycin system has been first evaluated in
vitro [15] and in transient in vivo studies [16,17] and since
then used with a variety of vector systems mainly for clin-
ical development [13]. So far the system has not been
described in transgenic mouse models.
We have constructed a two-vector based rapalog-inducible
system for STAT1 expression and evaluated applicability
in stable murine systems according to the above-men-
tioned requirements. Using stably transfected mouse
embryonic fibroblast (MEF) cell lines we proved induci-
bility, tightness of expression and the biological functions
of transgenically expressed STAT1 protein. We further-
more demonstrate rapalog-dependent STAT1 expression
in double-transgenic embryonic stem (ES) cells, thereby
providing a second, independent cell system for regulated
STAT1 expression. With respect to in vivo applicability for
transgenic mouse models, we demonstrate functionality
of the individual constructs and the proof of principle in
double-transgenic animals.
The inducible system described herein provides a novel
tool for the analysis of time- and dose-dependent STAT1
functions and will complement the knowledge obtained
from the analysis of STAT1-deficient cells and mice.
Results
Generation of a modified two-vector-based rapalog-
inducible system for STAT1 expression
The rapalog-inducible expression system comprises of the
rapalog binding components FRB (a mutated fragment
from the human FKBP rapamycin-associated protein
FRAP) and FKBP (FK506 binding protein) fused to a TAD
(a domain from the human p65/NFκB protein) and a
DBD (ZFHD1), respectively [16]. Both fusion proteins are
expressed from a bicistronic mRNA (separated by an IRES
sequence). Rapalog-dimerized DBD and TAD bind the
ZFHD1 recognition site upstream of a minimal IL2 pro-
moter. The DBD-TAD and the target gene components are
either located on separate or within one vector construct.
Our initial stable transfection experiments in murine
fibroblasts indicated background expression if all compo-
nents were present in one vector (data not shown) and we
therefore focused on the two-vector system (Fig. 1). The
original expression vector contains the transcription fac-
tor components under the control of the constitutive CMV
enhancer/promoter. This promoter is frequently silenced
in transgenic mouse models [18,19], thus we decided to
make use of two alternative constitutive promoters [20-
22]. We cloned the two transcription factor components
into an expression vector under the control of the elonga-BMC Biotechnology 2006, 6:48 http://www.biomedcentral.com/1472-6750/6/48
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tion factor (EF) 1α promoter [23] or the CMV enhancer/
β-actin promoter (ACT) [24], repectively (pEF::DBD-TAD,
pACT::DBD-TAD; Fig. 1A). The second vector was gener-
ated by insertion of the STAT1α cDNA into the ARGENT™
target vector (pZFHD1::mSTAT1; Fig. 1B).
STAT1 is expressed in a dose- and time-dependent manner 
and is stable after removal of the dimerizer
STAT1-deficient MEF cell lines were stably transfected
with the constructs pEF::DBD-TAD and
pZFHD1::mSTAT1 and clones were screened for STAT1
expression. To evaluate inducibility of the system, cells
were stimulated with rapalog and STAT1 expression was
determined using western blot (WB) analysis. Data are
shown for one representative clone (S2RS #8). STAT1 is
expressed in a dose- (Fig. 2A) and time- (Fig. 2B) depend-
ent manner upon rapalog treatment. STAT1 protein
expression in the stably transfected clone S2RS #8 reaches
similar levels as in wildtype (WT) cells upon 24 h treat-
ment with 50–100 nM rapalog. STAT1 protein expression
is detectable at about 2–4 h and protein levels further
increase up to at least 24 h treatment.
To investigate presence of STAT1 protein after removal of
dimerizer, cells were treated with rapalog for 12 h, washed
with PBS and further incubated in the absence of rapalog.
As shown in Fig. 2C, STAT1 protein was still detectable to
similar levels 12, 24 and 48 h after removal of the extra-
cellular dimerizer. Thus, as an important point for the in
vivo practicability of the system, active transcription factor
and/or STAT1 mRNA/protein stability is sufficient to
Schematic representation of the two vector types generated for inducible STAT1 expression Figure 1
Schematic representation of the two vector types generated for inducible STAT1 expression. pEF::DBD-TAD and 
pACT::DBD-TAD (A) encode the two transcription factor components under the control of the EF1α promoter or the CMV 
enhancer/β-actin promoter. The rapalog binding domain FRB (amino acids 2021–2113 of human FRAP with the threonine at 
amino acid position 2098 mutated to leucine) is fused to the transactivation domain (TAD) p65 (amino acids 361–551 of human 
NFκB); the second rapalog binding domain 3xFKBP (three tandemly repeated copies of human FKBP12) is fused to the DNA-
binding domain (DBD) ZFHD1 (a fusion of human transcription factors Zif268 and Oct-1); the two coding regions are sepa-
rated by an IRES sequence from encephalomyocarditis virus and both fusion proteins contain an amino-terminal nuclear locali-
zation signal. The second vector (pZFHD1::mSTAT1) is the target vector (B) and contains 12 repeats of the ZFHD1 
recognition site upstream of a minimal interleukin 2 (IL2) promoter. Murine STAT1α cDNA is tagged at the 5'- end with a min-
imal FLAG-sequence and fused at the 3'-end to the human β-globin splice sites to ensure stability of the mRNA. Zeocin, neo-
mycin and puromycin resistance genes, respectively, were used for selection of stably transfected cells. Restriction sites utilized 
for isolation of the DNA fragments used for stable transfection of ES cells (ES) or microinjection into zygotes (MI) are indi-
cated. Position of primers used for RT-PCR analysis of transgenic STAT1 mRNA expression are indicated (B). PCR amplicons 
from DNA and spliced mRNA are shown beneath. Vectors used for transfection of cells are cited in the text with "p" (e.g. 
pEF::DBD-TAD), constructs used for in vivo transgenesis without "p" (e.g. EF::DBD-TAD).BMC Biotechnology 2006, 6:48 http://www.biomedcentral.com/1472-6750/6/48
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ensure prolonged availability of STAT1 protein after elim-
ination of extracellular dimerizer.
IFNγ-mediated STAT1 activation is rapalog-dependent in 
STAT1-/- fibroblasts reconstituted with inducible STAT1
Next, we tested cytokine-induced STAT1 activation upon
rapalog treatment. WT, STAT1-/- cells and STAT1-/- cells
reconstituted with inducible STAT1 (S2RS #8) were stim-
ulated with rapalog and subsequently treated with IFNγ or
left untreated. STAT1 DNA-binding activity could be
detected after 12 h treatment over a range of 5–100 nM
rapalog, although, consistent with the protein expression
data, the level under these conditions is lower than in WT
cells. DNA-binding activity was observed from 4 h treat-
ment onwards with 100 nM rapalog (Fig. 2D) and further
increased with time. In addition to the rapalog-dependent
STAT1 homodimer formation also STAT1/STAT3 het-
erodimers could be detected in S2RS #8 cells upon IFNγ
stimulation, demonstrating that transgenic STAT1 can
interact normally with STAT3. In the absence of dimerizer
STAT1 DNA-binding activity was not detectable, further
substantiating the non-leakiness of the system. STAT1
DNA-binding activity (Fig. 2D) and STAT1 phosphoryla-
tion (data not shown) remained dependent on cytokine
stimulation, which is another important determinant for
the evaluation of a useful STAT1 expression system.
Inducible STAT1 protein is a biological active transcription 
factor
To examine the biological functions of the inducible
STAT1 protein we stimulated cells with IFNγ and analyzed
transcriptional activation of STAT1-dependent, IFNγ-
inducible genes. We performed semiquantitative RT-PCR
to detect guanylate binding protein 2 (GBP2) and interferon
regulatory factor 1 (IRF1) mRNA (Fig. 3A) and quantitative
RT-PCR (qPCR) to detect inducible nitrite oxide synthase
(iNOS) mRNA (Fig. 3B). The reconstituted clone S2RS #8
showed transcriptional induction of all three genes upon
IFNγ stimulation in the presence of rapalog. Without rap-
alog gene induction was not detected, again underlining
the tightness of the expression system. STAT1-/- cells stably
expressing the transcription factor components only
(SpEF #2) did not show gene induction upon IFNγ treat-
ment in both, the absence or presence of rapalog. Quanti-
tative analysis of iNOS mRNA expression revealed similar
IFNγ-mediated induction in S2RS #8 and WT cells. Impor-
tantly, rapalog treatment did not influence the transcrip-
tional activity of STAT1 in IFNγ-stimulated WT cells (Fig.
3A). The slight increase in iNOS mRNA expression in rap-
alog/IFNγ-treated WT cells (Fig. 3B) was not consistently
observed. As shown for GBP2 and IRF1, iNOS mRNA was
not induced in STAT1-/- and SpEF #2 cells upon rapalog
and/or IFNγ treatment. Consistent with the data for STAT1
DNA-binding activity, also gene induction remained
dependent on a cytokine stimulus in STAT1-expressing
Inducible STAT1 expression in stably transfected MEF cell  lines Figure 2
Inducible STAT1 expression in stably transfected MEF cell 
lines. WT, STAT1-/- (S1-/-) and STAT1-/- cells reconstituted 
with inducible STAT1 (S2RS #8) were treated with rapalog at 
the dose indicated for 24 h (A) or treated with 100 nM rapa-
log for the times indicated (B). To analyze STAT1 protein 
stability, cells were treated with 100 nM rapalog for 12 h, 
washed three times with PBS and further incubated without 
inducer. STAT1 protein expression was determined with 
WB analysis and loading was controlled via probing for ERK 
protein (A-C). Cells were treated as in A and B, stimulated 
with 100 U/ml IFNγ for 15 min or left untreated, lysed and 15 
μg total cell extract subjected to EMSA analysis using hSIE 
oligonucleotides as probes (D). Similar results were obtained 
with other reconstituted clones.BMC Biotechnology 2006, 6:48 http://www.biomedcentral.com/1472-6750/6/48
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cells. These results demonstrate the biological activity of
the inducible STAT1 transgene at the example of three
independent target genes.
Inducible STAT1 protein can mediate antiviral protection
STAT1 is crucial for the IFNγ-induced defense against
vesicular stomatitis virus (VSV) infection [7]. To show that
inducibly expressed STAT1 protein is also able to restore
complex biological functions, we analyzed antiviral activ-
ity against VSV infection. IFNγ induced antiviral activity in
rapalog-pretreated but not in untreated S2RS #8 cells (Fig.
4). The amount of IFNγ required for resistance against VSV
was similar in rapalog-treated S2RS #8 and WT cells. Rap-
alog treatment of WT, STAT1-/- and SpEF #2 cells did not
influence intrinsic or IFNγ-induced resistance against VSV
infection (data not shown). Hence, STAT1-dependent
IFNγ responses involving multiple and complex mecha-
nisms can be inducibly restored with this STAT1 expres-
sion system.
Stably transfected embryonic stem (ES) cells express 
transgenic STAT1 protein dependent on the presence of 
rapalog
To test the rapalog-inducible STAT1 system in another
independent cell system, we stably transfected ES cells
with the two constructs EF::DBD-TAD and
ZFHD1::mSTAT1. We identified several clones with differ-
ent expression levels of rapalog-inducible STAT1. Clone
#A7 expressed low transgenic STAT1  mRNA levels,
whereas in clone #B5 rapalog-induced STAT1 expression
was as high as in the MEF cell line S2RS #8 (Fig. 5A). As
expected, no transgenic STAT1 mRNA was detected in WT
ES cells. Expression levels of endogenous STAT1 mRNA in
ES cell clones #A7 and #B5 was similar to WT ES cells,
demonstrating that induction of transgenic STAT1 expres-
sion has no obvious influence on endogenous STAT1
expression (data not shown). Rapalog-dependent increase
of STAT1 protein was clearly detectable in clone #B5, but
was not observed in clone #A7 (Fig. 5B). Accordingly, the
expression level of both transcription factor components
TAD and DBD in clone #B5 was similar to the level in MEF
cell line S2RS #8 (Fig. 5C). Increase of STAT1 protein level
is difficult to analyze in ES cells since they express endog-
enous STAT1 and for as yet unknown reasons, we could
not detect the minimal FLAG-tag fused to the transgenic
STAT1. Expression of STAT1 protein upon rapalog treat-
ment in clone #B5 clearly exceeds WT levels and, as
another important point for the analysis of STAT1 func-
tion, does not lead to dramatic overexpression. Taken
together, these data show that this dimerizer-inducible
expression system is suitable for the use in ES cells.
Rapalog-induced antiviral activity in IFNγ-treated MEF cell  lines Figure 4
Rapalog-induced antiviral activity in IFNγ-treated MEF cell 
lines. Cells were treated with 100 nM rapalog for 4 h or left 
untreated and subsequently stimulated with serial two-fold 
dilutions of IFNγ (starting with 100 U/ml) for 8 h or left 
untreated. Cells were then challenged with VSV (moi = 1) 
and surviving cells were stained with crystal violet 36 h post 
infection.
Inducible IFNγ-mediated induction of STAT1 target genes in  MEF cell lines Figure 3
Inducible IFNγ-mediated induction of STAT1 target genes in 
MEF cell lines. Cells were treated with 100 nM rapalog for 24 
h or left untreated and subsequently stimulated with IFNγ 
(100 U/ml) for 4 h or left untreated. Total RNA was used for 
RT-PCR analysis for GBP2 and IRF1 expression; cyclophilin was 
used as endogenous control (A). Quantitative RT-PCR was 
performed for iNOS expression, HPRT was used for normali-
zation; one representative of two independent experiments 
is shown (B).BMC Biotechnology 2006, 6:48 http://www.biomedcentral.com/1472-6750/6/48
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The two individual components of the expression system 
are functional as transgenes
To test the applicability of the two individual vector com-
ponents as transgenes respective constructs were microin-
jected into zygotes. Three mouse lines transgenic for the
ZFHD1::mSTAT1 were obtained by DNA-microinjection
and analyzed for transgene expression. Since no gene
expression occurs from this construct in the absence of the
transcription factor components and the dimerizer, we
isolated primary embryonic fibroblasts (PEF), transiently
transfected the pEF::DBD-TAD construct and analyzed
rapalog-inducible transgenic STAT1  mRNA expression.
Data are shown for PEF from four embryos of two individ-
ual mice (#540, #739) from the same transgenic mouse
line (#82). PEF from at least one embryo per mouse
expressed transgenic STAT1 mRNA (Fig. 6A). As in the sta-
bly transfected MEF cell lines, STAT1  expression was
strictly dependent on rapalog stimulation in the trans-
genic situation. Similar results were obtained with a sec-
ond transgenic mouse line, whereas the third line
analyzed did not show any STAT1 expression (data not
shown). These data prove the functionality of the STAT1
target construct (ZFHD1::mSTAT1) as a transgene in vivo.
Notably, even in the presence of high amounts of the tran-
scription factor components in the transient transfection
experiment,  STAT1  expression remained dependent on
rapalog.
Mice transgenic for the transcription factor components
were initially generated with the EF::DBD-TAD construct.
Several transgenic mouse lines generated either via DNA-
microinjection or via blastocyst injection of pre-screened
ES cells showed ubiquitous but low expression of the tran-
scription factor components as compared to the MEF cell
line S2RS #8 or the ES cell clone #B5 (data not shown).
Amongst nine transmitting mouse lines, five lines
expressed the DBD-TAD mRNA, but only one of them
showed detectable TAD protein expression. Expression
levels of transcription factor domains were in all mice
clearly lower than in the MEF cell lines and ES cells stably
transfected with the same construct (Fig. 6B and data not
shown). In contrast, analysis of PEF from mice generated
by blastocyst injection of ES cells transgenic for the tran-
scription factor components under the control of the CMV
enhancer/β-actin promoter (ACT) revealed higher expres-
sion of TAD than in PEF derived from EF::DBD-TAD mice.
TAD protein level was comparable to that in S2RS #8 cells
and hence should be sufficient for inducible STAT1
expression (Fig. 6B). The transcription factor components
in ACT::DBD-TAD mice were expressed in all tissues
tested, although the expression level varied amongst dif-
ferent tissues (Fig. 6C). Heart, liver, lung and muscle
showed high expression of TAD, whereas in brain, spleen
and testis the expression level of transcription factor com-
ponents was significantly lower and barely detectable in
Expression analysis of inducible STAT1 and transcription fac- tor components in double-transgenic ES cells Figure 5
Expression analysis of inducible STAT1 and transcription fac-
tor components in double-transgenic ES cells. ES cells were 
stably transfected with the constructs EF::DBD-TAD and 
ZFHD1::mSTAT1. WT ES cells and two representative dou-
ble-transgenic clones (#A7 and #B5) were treated with 100 
nM rapalog or left untreated, lysed and analyzed for inducible 
STAT1 expression. RT-PCR was performed to detect trans-
genic STAT1 mRNA and normalized to cyclophilin (A). WB 
was performed to detect STAT1 protein as described in the 
legend to Fig. 2(B). Expression of the FRB-p65 fusion protein 
(TAD; ~48 kDa) in ES cell clone #B5 was determined by WB 
analysis in comparison to the S2RS #8 MEF cell line. Expres-
sion of the DBD fusion protein (~50 kDa) is shown by WB 
on the rapalog-binding domain FKBP12 in ES cell line #B5 and 
the MEF cell line S2RS #8 with respective WT cells. Endog-
enous p65/NFκB (65 kDa) is shown as loading control (C).BMC Biotechnology 2006, 6:48 http://www.biomedcentral.com/1472-6750/6/48
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kidney. In addition, we observed that TAD expression also
varied amongst individual mice and littermates. The
majority of mice analyzed showed lower expression level
of the transcription factor than the MEF cell line S2RS #8
and the ES cell clone used for the generation of these mice
(data not shown).
Double-transgenic mice (ACT::DBD-TAD × 
ZFHD1::mSTAT1) show inducible transgenic STAT1 
mRNA upon rapalog stimulation
To investigate whether the amount of transcription factor
components in ACT::DBD-TAD mice (line #1) is sufficient
to induce transgenic STAT1 in vivo, these mice were
crossed with three different ZFHD1::mSTAT1 mouse lines
(#37, #50, #82). PEF were isolated from single embryos,
genotyped and double-transgenic clones were first
screened for expression of the transcription factor compo-
nents. PEF from one out of six embryos showed high
expression levels of the transcription factor components
(Fig. 7A). In PEF #23 TAD expression was similar to the
MEF cell line S2RS #8, whereas PEF derived from all other
embryos showed clearly lower expression levels (Fig. 7A).
Next, we stimulated these double-transgenic PEF with rap-
alog and analyzed transgenic STAT1 mRNA expression by
RT-PCR. Basal expression of transgenic STAT1  was not
seen in PEF from any of the embryos tested, thereby prov-
ing the tightness of the system also in vivo. Transgenic
STAT1 mRNA could be induced upon rapalog stimulation
in PEF #23, which had high TAD expression levels (Fig.
7B), but not in cells with low TAD expression. Although
STAT1 mRNA was clearly induced, we could not detect
STAT1 protein against the background of endogenous
STAT1 (data not shown). However, this set of experiments
shows that transgenic STAT1  can be induced in PEF
derived from double-transgenic mice and that the dimer-
izer-based system is in principle functional in transgenic
mouse models.
Discussion
In this study we established a rapalog-inducible expres-
sion system for STAT1. Using STAT1-/- MEF cell lines stably
reconstituted with the inducible STAT1 expression system,
we show that STAT1 protein is tightly controllable: in the
absence of inducer no expression is detectable and the
amount of expression is dependent on the dose of dimer-
izer applied. Although expression levels varied, as
expected, amongst different clones, a reconstituted cell
line with STAT1 levels up to WT cells could be obtained.
Induction occurs rapidly, increases over time and STAT1
protein is stable after removal of dimerizer for at least up
to 48 h (Fig. 2). Inducible STAT1 protein is biologically
active and can restore the IFNγ response defects in STAT1-
/- cells. No effects on IFNγ responses were observed in cells
expressing the DBD-TAD domains alone (Fig. 3 and 4).
We generated stably transfected ES cells and proved the
Expression analysis of single-transgenic mice for the  ZFHD1::mSTAT1 or the ACT::DBD-TAD construct Figure 6
Expression analysis of single-transgenic mice for the 
ZFHD1::mSTAT1 or the ACT::DBD-TAD construct. Mice 
transgenic for the target construct ZFHD1::mSTAT1 (line 
#82) were crossed with non-transgenic mice. PEF were iso-
lated from individual embryos at day 14, transfected with 
pEF::DBD-TAD, stimulated with 100 nM rapalog for 24 h or 
left untreated and subjected to RT-PCR analysis for trans-
genic STAT1 expression; cyclophilin was used as endogenous 
control (A). PEF were isolated from each embryo separately 
of transgenic mice (ACT::DBD-TAD, line #1 and EF::DBD-
TAD, line #103), lysed and subjected to WB for analyzing 
expression of TAD compared to MEF line S2RS #8. Loading 
was controlled with p65/NFκB (B). Protein was isolated from 
different organs of transgenic mice and WB was performed 
detecting TAD subunit. As loading control a SDS-PAGE was 
performed and stained with Coomassie (C).BMC Biotechnology 2006, 6:48 http://www.biomedcentral.com/1472-6750/6/48
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functionality of the STAT1 expression system in an inde-
pendent cell type and in a STAT1+/+ background (Fig. 5).
Recently, inducible expression systems have been
described for the use in ES cells, mainly based on the tet-
racycline system [25]. To our knowledge this is the first
report, demonstrating dimerizer-based inducible gene
expression in ES cells.
We present several attempts to apply this system in trans-
genic mouse models and prove the principle of in vivo
applicability. We analyzed the functionality of each of the
constructs of the two vector-based system in single-trans-
genic mice (ZFHD1::mSTAT1 and EF::DBD-TAD, respec-
tively) and show that inducible expression can be
achieved by transient transfection with the respective sec-
ond construct. Expression of STAT1 remained strictly
dependent on the dimerizer even in the presence of access
of either of the two constructs (Fig. 6A and data not
shown). Transgenic mice for the transcription factor com-
ponents under the control of the EF1α promoter
(EF::DBD-TAD) showed ubiquitous but low level of
expression. PEF from double-transgenic mice obtained by
crossing ZFHD1::mSTAT with EF::DBD-TAD did not show
any STAT1 induction upon rapalog treatment. Lack of
STAT1 induction in these mice is most likely due to the
low expression of the transcription factor components,
since direct correlation of DBD-TAD expression and target
gene expression has been reported before [13]. In con-
trast, mice transgenic for the transcription factor compo-
nents under the control of the CMV enhancer/β-actin
promoter [24] (ACT::DBD-TAD) showed higher expres-
sion levels of the transcription factor components. At least
in PEF from one embryo tested, expression levels were
similar to the levels obtained in the stable transfected MEF
and ES cell clones that do express sufficient amounts for
STAT1 protein induction (Fig. 6B). Higher in vivo expres-
sion correlated with higher expression levels in ES cells in
vitro (data not shown). Unfortunately, the expression pat-
tern of DBD-TAD in these mice was variegated between
organs and even between full siblings (Fig. 6C and data
not shown), a phenomenon that has been widely
described for transgenic animals [26,27]. Upon crossing
these mice with single-transgenic ZFHD1::mSTAT1 mice,
PEF from one out of six embryos showed inducible STAT1
expression.  STAT1  expression was again dependent on
rapalog stimulation proving the non-leakiness of the sys-
tem  in vivo.  STAT1  inducibility correlated with high
expression of DBD-TAD, further underlining that suffi-
cient DBD-TAD expression is one of the limiting factors of
the system (Fig. 7). However, we could not detect trans-
genic STAT1 protein against the background of endog-
enous STAT1 even in the presence of high amounts of
transcription factor components (data not shown). One
possible explanation is, that transgene silencing effects
[28] also occur in ZFHD1::mSTAT1 mice and that the
accessibility of the target promoter is also gene locus
dependent. Since transient transfection of DBD-TAD into
cells derived from these mice does lead to sufficient STAT1
induction (Fig. 6A and data not shown) it is most likely a
combinatorial effect of the integration loci of both con-
structs. One possible solution would be to screen a large
number of independent single- and double-transgenic
animals for stable and sufficient DBD-TAD expression
and STAT1 inducibility. Since this is a very time- and ani-
mal-intensive approach, future studies will focus on
homologous integration of both, DBD-TAD and
ZFHD1::mSTAT1 separately into ES cells. Single copy inte-
gration of the transgenes into established loci in the
mouse genome should avoid any silencing mechanisms
and ensure defined and stable expression levels in vivo
[29]. Variegated DBD-TAD expression amongst individu-
als/littermates and the crucial role of DBD-TAD levels for
STAT1 induction makes in vivo rapalog treatment experi-
ments with ZFHD1::mSTAT1 × ACT::DBD-TAD mice cur-
rently inpracticable. Additional complexity in variability
might come from interindividual differences in pharma-
Expression of transcription factor components and trans- genic STAT1 in double-transgenic mice Figure 7
Expression of transcription factor components and trans-
genic STAT1 in double-transgenic mice. PEF were isolated 
from double-transgenic mice (ACT::DBD-TAD line #1 × 
ZFHD1::mSTAT1) and stimulated with rapalog (100 nM) for 
24 h or left untreated (A, B). Cells were lysed, and WB was 
performed to detect TAD. p65/NFκB was used as endog-
enous control (A). RNA was isolated and RT-PCR per-
formed to detect transgenic STAT1 mRNA; cyclophilin was 
used as endogenous control (B).BMC Biotechnology 2006, 6:48 http://www.biomedcentral.com/1472-6750/6/48
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cokinetics and/or intracellular bioavailability of the tran-
scription factor components and rapalog. At this stage this
cannot formally be excluded. However, in vivo functional-
ity of rapamycin-derivatives as synthetic inducers of bio-
logical functions and of the transcription factor
components in various cellular environments has been
demonstrated [30-32]. In contrast to other synthetic
inducible expression systems, i.e. ecdysone or tetracycline
[12], the TAD used here might undergo post-translational
modifications. Indeed, in preliminary experiments we
have observed conditional phosphorylation of TAD at
one specific site paralleling the modification of the endog-
enous p65/NFκB (data not shown). In vitro, in MEF cell
lines and ES cells, phosphorylation-independent TAD
activity leading to rapalog-induced STAT1 expression has
been demonstrated (Fig. 2 and 5). Further studies are
required to address the dependence of TAD activity on the
status of the endogenous p65/NFκB regulation with
respect to additional known phosphorylation sites and
different cellular contexts. However, variegated expression
of the DBD-TAD components is currently the crucial point
for  in vivo functionality of this system. Therefore, this
makes it to our opinion worthwhile to solve the issue of
obvious chromatin positioning effects on the transgenes.
For the use of inducible expression systems no or minimal
off-target effects are preferable. As with other systems, pos-
sible side-effects cannot be excluded and have to be
assessed for each specific application. Here, no off-target
effects concerning the dimerized transcription factor com-
ponents or rapalog treatment alone could be observed in
two independent biological assay conditions (Fig. 3 and
4).
In summary, the rapalog-inducible STAT1 expression sys-
tem established in this report provides a novel tool to
study dose- and time-dependent STAT1 functions in
fibroblasts and embryonic stem cells. Our attempts to
introduce the system into transgenic mice gave proof of
principle functionality and future directives for improve-
ments.
Conclusion
Inducible temporal gene expression systems are indispen-
sable tools for fine-tuned analysis of gene functions. All
reported systems have some limitations [33]. Here we
report the application of a novel rapalog-inducible STAT1
expression system in vitro and in vivo. STAT1 is a transcrip-
tional activator central for the signaling of a variety of
cytokines and growth factors. STAT1 functions range from
immune regulation to tumorigenesis and timely availabil-
ity of STAT1 protein is thought to be crucial for (ab-)nor-
mal cellular function. We show that rapalog-induced
STAT1 expression in vitro is highly inducible and tightly
controllable demonstrating the potential of this inducible
system. Using reconstitution experiments we show that
rapalog-induced STAT1 fulfills all main STAT1 functions
and thus is a novel tool to unravel STAT1 functions in a
time- and dose-dependent manner.
We show that rapalog-inducible STAT1 expression can be
achieved in vivo, although STAT1 induction is impaired by
transgene silencing effects in transgenic mice harbouring
randomly integrated gene constructs. These effects can be
avoided by stable integration of single copies of each
expression vector into established loci in the mouse
genome. An inducible STAT1 expression system in vivo
could identify STAT1-independent gene functions in sev-
eral knockout mice with reduced STAT1 level. A rapalog-
inducible expression system would also be a powerful
alternative to existing inducible expression systems in vivo.
Methods
Expression vectors
Transcription factor domains of the vector pC4N2-RHS/
ZF3 (ARIAD Pharmaceuticals, Inc.) were cloned into the
expression vector pEF-zeo (kindly provided by Pavel
Kovarik, Max F. Perutz Laboratories, University of Vienna,
Austria) [23,34], containing the EF1α promoter and a
zeocin resistance gene. A second vector containing the
transcription factor domains under the control of a CMV
enhancer/β-actin promoter [24] was cloned into pKO-
sc920 (Lexicon Genetics) containing a neomycin resist-
ance cassette. STAT1α cDNA (kindly provided by Chris
Schindler, Columbia University, New York) [35] was N-
terminal tagged with a FLAG (MDYKDED, [36]) and a
human β-globin splice (GenBank accession no. U01317,
nt 62553–64242) was added to the 3'-end. The modified
STAT1α cDNA was cloned into the target vector pZ12I-PL2
(ARIAD Pharmaceuticals, Inc.) and a puromycin resist-
ance gene (from the vector pKOSelect-PuroV810; Lexicon
Genetics) was inserted downstream of the STAT1α cDNA.
Reagents
Purified, recombinant murine IFNγ was obtained from
Calbiochem. Antibodies were purchased from Santa Cruz
(STAT1α p91 (M-23)), Upstate (Anti-NF-κB p65, CT),
Transduction Laboratories (pan ERK) and Biovision
(FKBP12) respectively, and used at dilutions of 1:250
(FKBP12) or 1:1000 (all other antibodies). HRP-coupled
anti-rabbit antiserum and anti-mouse IgG were used from
Sigma Aldrich and Amersham Biosciences, respectively
(1:2000 dilutions). Rapalog AP21967 [14] was obtained
from ARIAD Pharmaceuticals, Inc. and used at concentra-
tions and times indicated. Coomassie staining was per-
formed with Bio-Safe Coomassie Stain (BioRad).
Cell culture
Primary embryonic fibroblasts (PEF) were isolated as
described [37]. Wildtype (WT) embryonic fibroblast cellBMC Biotechnology 2006, 6:48 http://www.biomedcentral.com/1472-6750/6/48
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lines (MEF) were generated by spontaneous immortaliza-
tion. The STAT1-deficient cell line was kindly provided by
David Levy (New York University School of Medicine,
New York) [6]. Fibroblasts were cultured in DMEM sup-
plemented with 10 % FCS, 100 μg/ml penicillin, 100 U/
ml streptomycin, and 1 mM L-glutamine (Invitrogen).
E14.1 embryonic stem (ES) cells (129/OlaHsd) were cul-
tured as described [11]. Bone marrow-derived macro-
phages were isolated and grown as described [38].
Cell transfection, selection of transgenic clones
Transfections of immortalized fibroblasts with both con-
structs (pEF::DBD-TAD and pZFHD1::mSTAT1) were per-
formed with TransFast™ reagent (Promega Corporation),
all other transfections with Nucleofector technology
(Amaxa Inc.) according to the manufacturer's instruc-
tions. For selection of stably transfected fibroblasts 5 μg/
ml puromycin (Sigma Aldrich) and/or 500 μg/ml zeocin
(Invitrogen) was used. Stably transfected ES cells were
selected using 40 μg/ml zeocin, 0.4 μg/ml puromycin or
0.2 mg/ml G418 (Invitrogen).
Generation of transgenic mice
Transgenic mice were either generated by microinjection
of each of the vectors separately into zygotes or by blasto-
cyst injection of transgenic ES cells. DNA fragments for
microinjection (MI) or transfection of ES cells (ES) for
blastocyst injection were isolated by digestion at sites
indicated (Fig. 1). All animal experiments were conducted
in accordance with protocols approved by the Austrian
laws and European directives.
Western Blot (WB) and Electrophoretic Mobility Shift 
Assay (EMSA)
1 – 5 × 105 cells were lysed and 10–15 μg protein used for
WB and EMSA analysis as previously described
[11,39,40].
RT-PCR
Total RNA was isolated with Trizol Reagent (Invitrogen).
cDNA was synthesized using Oligo(dT)12–18 primer and
SuperScript™ II Reverse Transcriptase (Invitrogen). The
following primers were used for RT-PCR: cyclophilin 5'-
GAC GCC ACT GTC GCT TTT CG-3' and 5'-CAG GAC ATT
GCG AGC AGA TGG-3', IRF1 5'-CAG AGG AAA GAG AGA
AAG TCC-3' and 5'-CAC ACG GTG ACA GTG CTG G-3',
GBP2 5'-TGC TAA ACT TCG GGA ACA GG-3' and 5'-GAG
CTT GGC AGA GAG GTT TG-3, transgenic STAT1 5'-TCT
GTG TCT GAA GTC CAC C-3' and 5'-CAA GAA AGC GAG
CTT AGT GAT AC-3' and DBD-TAD (transcription factor
components) 5'-AGG CTG GGA AGA AGG GGT TGC-3'
and 5'-GCC AGA AGT CAG ATG CTC AAG-3.
Quantitative RT-PCR (qPCR)
Total RNA was isolated with Trizol Reagent (Invitrogen),
DNA contaminations were removed by treatment with
RQ1 RNase free DNase (Promega Corporation) and
cDNA was transcribed using the iScript cDNA Synthesis
Kit (BioRad). qPCR was performed as described [41]
except that 1U Firepol (Solis BioDyne) with the according
buffer B per reaction was used and the thermal cycling
conditions were the following: 15 min at 95°C followed
by 40 cycles of 15 sec at 95°C and 55 sec at 60°C. Primers
used for iNOS qPCR: 5' TGG TCC GCA AGA GAG TGC T
3' (iNOS-fwd) and 5' CCT CAT TGG CCA GCT GCT T 3'
(iNOS-rev). The oligonucleotide used as probe (5' FAM-
CCC GGC AAA CCC AAG GTC TAC GTT C-BHQ1 3') was
labeled at the 5'-end with the reporter dye 6- carboxyfluo-
rescein (FAM) and at the 3'-end with the quencher dye
blackhole quencher1 (BHQ1). The qRT-PCR assays for
iNOS were submitted to the Real-Time Primer and Probe
Database (RTPrimerDB identification no. 3483) [42].
HPRT  was used as endogenous control (RTPrimerDB
identification no. 3600) and the calculation of qPCRs was
performed as described [41]; data were calibrated to the
untreated state of the respective genotype.
Antiviral Assays
Antiviral assays with vesicular stomatitis virus (VSV, Indi-
ana strain) were performed as described [7].
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